Resmed Inc: (NYSE: RMD)

$50.02

0.30 (0.60%)

Volume 757,688

May 23 04:06 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		49.30 - 50.12
	
		52wk Low - High
		29.82 - 51.40
	
		Previous Close
		49.72
	
		Avg. Volume
		995,621
	
		Industry
		MED PRODUCTS
	
		Market Cap
		7.13 B
	
		Div - Yield
		0.68 - 1.37
	
		Beta
		0.70
	
		PE (Forward)
		22.06
	
		Current Year Est.
		2.25
	
		Quarterly Earnings ESP 
		1.59%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		184 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/10/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            22.06
                        
                            PEG Ratio
                            1.43
                        
                            Current Year Est.
                            2.25
                        
                            Current Quarter Estimate
                            0.63
                        
                            Most Accurate Estimate
                            0.64
                        
                            Earnings ESP 
                            1.59%
                        
                            Next Earnings Report Date
                            08-08-2013
                        
                            EPS Last Year
                            2.15
                        
                            Expected Earnings Growth
                            15.41%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
ResMed Inc. is a leading designer, manufacturer and distributor of medical equipment for treating and diagnosing sleep disordered breathing.  Sleep disordered breathing includes sleep apnea and related respiratory conditions.  The company sells a comprehensive range of diagnostic and treatment devices in countries through a combination of wholly owned subsidiaries and independent distributors.   
Full RMD Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
RMD Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (06/2013)	Next Year (06/2014)
Average Estimate	0.63	0.56	2.25	2.48
Number of Estimates	4	4	7	6
Low Estimate	0.61	0.54	2.23	2.41
High Estimate	0.69	0.58	2.30	NA
Year Ago EPS	0.54	0.49	1.74	2.25
EPS Growth	16.67%	13.78%	29.56%	10.01%

More RMD Estimates

Average Earnings Estimates for RMD

EPS Growth for RMD

Industry Analysis

Name	Symbol	Previous Close
RESMED INC	RMD	49.72
ATRICURE INC	ATRC	9.14
CONCEPTUS INC	CPTS	30.94
INVIVO THERAPT	NVIV	2.90
TRANS1 INC	TSON	1.80
ABAXIS INC	ABAX	43.51
ADVAXIS INC	ADXS	0.04
BAXTER INTL	BAX	72.30
BIO-RAD LABS -A	BIO	115.39
BIOLIFE SOL INC	BLFS	0.37

Sector:Medical>> Industry:MED PRODUCTS

COMPARE TICKER vs. Its Peers

Zacks Commentary

ResMed's Earnings Beat; Revs Lag

Apr 29, 2013

ResMed Protects Patent Landscape

Apr 02, 2013

Another Study for STJ's EnligHTN

Feb 22, 2013

Safeway Ticks Higher on 4Q Results

Feb 22, 2013

Symmetry Misses but Up Y-Y

Feb 22, 2013

Align Upgraded to Neutral

Feb 20, 2013

BioScrip Reaffirmed at Neutral

Feb 20, 2013

Qiagen in Collaboration with Lilly

Feb 15, 2013

More RMD Zacks Commentary

Financials

EPS TTM	2.15
Sales	1,369
Net Income	311
Price/Earnings	23.13
Price/Book	4.03
Price/Cash Flow	20.57
Price/Sales	4.85

More RMD Financials

News

ResMed (RMD) Showing Support Near $48.78 With 1.36% Dividend Yield - Freshbrewedmedia

May 23, 2013

ResMed Crosses Above its 10-day MA (RMD) - Financial News Network Online - Moving Average Crossovers

May 22, 2013

ResMed (RMD) Trading Near $50.59 Resistance Level - Freshbrewedmedia

May 17, 2013

ResMed Shares Sinking Lower, Down 1.2% - Financial News Network Online - Market Movers

May 15, 2013

ResMed: 52-Week High Recently Eclipsed (RMD) - Financial News Netwfork Online - 52-Week High-Lows

May 14, 2013

Shares of ResMed Rise to a New 52-Week High - Financial News Netwfork Online - 52-Week High-Lows

May 13, 2013

Recent 52-Week High Exceeded in Shares of ResMed (RMD) - Financial News Netwfork Online - 52-Week High-Lows

May 10, 2013

Shares of ResMed Have Risen Above Previous 52-Week High - Financial News Netwfork Online - 52-Week High-Lows

May 8, 2013

See All News Stories on RMD

Broker Recommendations

Current ABR	2.36
ABR (Last Week)	2.36
# of recs in ABR	11
Average Target Price	44.97
Industry Rank by ABR	184 out of 265
Rank in Industry	5 out of 73

More RMD Broker Recommendations

Day Low - High	49.30 - 50.12
52wk Low - High	29.82 - 51.40
Previous Close	49.72
Avg. Volume	995,621
Industry	MED PRODUCTS
Market Cap	7.13 B
Div - Yield	0.68 - 1.37
Beta	0.70
PE (Forward)	22.06
Current Year Est.	2.25
Quarterly Earnings ESP	1.59%

PE (Forward)	22.06
PEG Ratio	1.43
Current Year Est.	2.25
Current Quarter Estimate	0.63
Most Accurate Estimate	0.64
Earnings ESP	1.59%
Next Earnings Report Date	08-08-2013
EPS Last Year	2.15
Expected Earnings Growth	15.41%

Username: Password:

Remember me [?]

Resmed Inc: (NYSE: RMD)

$50.02

0.30 (0.60%)

Volume 757,688

May 23 04:06 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED PRODUCTS

Zacks Commentary

Financials

News

Broker Recommendations